Showing 5181-5190 of 7316 results for "".
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- New Assessment Tool for Chronic Prurigo Shows Power of Patient Reportinghttps://practicaldermatology.com/news/development-and-validation-of-a-patient-reported-outcome-measure-to-assess-disease-control-in-chronic-prurigo/2462214/Researchers have introduced a 5-item Prurigo Control Test (PCT), in what could be the first patient-reported outcome measure for determining disease control for chronic prurigo (CPG). This tool, according to the researchers, was designed to assess disease control in CPG
- FDA Gives Nod to Marketing DermaSensor for Skin Lesion Evaluationhttps://practicaldermatology.com/news/fda-gives-nod-to-dermasensor-for-skin-lesion-evaluation/2462213/The U.S Food and Drug Administration (FDA) announced that it has granted authorization for marketing for the DermaSensor (DermaSensor Inc.) prescription device, indicated for the evaluation of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients ag
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeuti
- Skin Deep Solutions: Navigating Acne and Rosacea with Quality Skin Carehttps://practicaldermatology.com/news/skin-deep-solutions-navigating-acne-and-rosacea-with-quality-skin-care/2462209/In the ever-evolving landscape of dermatology, Hilary Baldwin, MD, a board-certified dermatologist, and the medical director of the Acne Treatment & Research Center in Brooklyn, recently shed light on the critical role
- Study: Transgender Individuals Experience Stigma, Treatment Barriershttps://practicaldermatology.com/news/lived-experience-of-acne-and-acne-treatment-in-transgender-patients/2462206/New research sheds light on the lived experiences of transgender individuals who have acne. "While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in g
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the
- Researchers ID Genetic Risk Factors for Early-Onset Merkel Cell Carcinomahttps://practicaldermatology.com/news/researchers-id-genetic-risk-factors-in-early-onset-mcc/2462201/New research indicates that germline variants in genes are significantly associated with early-onset Merkel cell carcinoma (MCC). The case-control study included 1,012 individuals (37 of whom had early-onset MCC, 45 with later-onset MCC, and 930 controls) who were prospectively enrolled